VRDN 8-K 2026-11-04

Viridian Therapeutics, Inc.\DE (VRDN) 8-K dated 2026-11-04 — accession 0001193125-26-446200.

Viridian Therapeutics, Inc.\DE (VRDN) is a biotechnology company listed on US.

Viridian Therapeutics, Inc.\DE filed a 8-K on 2026-11-04. Accession 0001193125-26-446200.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported VRDN revenue for 2025-12-31 was $70.8M. Net income was -$342.6M. Revenue was up 23359.9% from 2024-12-31 to 2025-12-31. VRDN currently screens at market cap $1.39B.

Not investment advice. The VRDN SEC hub lists recent forms. The stock page is the research view.